Dr. Reddy’s Projects 50% Growth In U.S. OTC Business
This article was originally published in The Tan Sheet
Executive Summary
The Indian private labeler predicts annualized U.S. OTC sales of $200 million by March 2013. Dr. Reddy’s recently launched an equivalent of Allegra-D 24 Hour and plans to introduce generic Prevacid 24HR in its next fiscal year.
You may also be interested in...
Dr. Reddy’s Moves Quick On First Generic Allegra-D 12 Hour Extended Release
Generics of fexofenadine-only Allegra and fexofenadine/pseudoephedrine Allegra-D 24 Hour launched soon after the branded product’s switch in 2011, Dr. Reddy’s abbreviated NDA for a generic of Allegra-D 12 Hour Allergy & Congestion is the first approved by FDA.
Dr. Reddy’s Moves Quick On First Generic Allegra-D 12 Hour Extended Release
Generics of fexofenadine-only Allegra and fexofenadine/pseudoephedrine Allegra-D 24 Hour launched soon after the branded product’s switch in 2011, Dr. Reddy’s abbreviated NDA for a generic of Allegra-D 12 Hour Allergy & Congestion is the first approved by FDA.
Perrigo’s Mucinex Equivalent On The Cusp, But New Product Outlook Dims
The private labeler’s long-delayed guaifenesin launch now tentatively is set for March, CEO Joseph Papa says. But unclear timelines for other OTC launches caused Perrigo to lower its fiscal year consolidated new product sales outlook to $150 million from an initial projection of more than $190 million.